PDT Partners’s Ligand Pharmaceuticals LGND Stock Holding History

PDT Partners’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-11,061	Closed	-$704K	–	532
2016 Q3	$704K	Sell	11,061 -89,607	-89%	-$6.58M	0.04%	343
2016 Q2	$7.49M	Sell	100,668 -10,901	-10%	-$809K	0.59%	19
2016 Q1	$7.45M	Buy	111,569 +24,686	+28%	+$1.5M	0.47%	27
2015 Q4	$5.88M	Buy	86,883 +50,976	+142%	+$3.15M	0.81%	9
2015 Q3	$1.92M	Buy	35,907 +2,510	+8%	+$152K	0.04%	473
2015 Q2	$2.1M	Buy	33,397 +1,675	+5%	+$91.4K	0.06%	415
2015 Q1	$1.53M	Buy	+31,722	New	+$1.22M	0.04%	557
2014 Q4	–	Sell	-31,066	Closed	-$911K	–	885
2014 Q3	$911K	Buy	31,066 +4,368	+16%	+$145K	0.02%	705
2014 Q2	$1.04M	Buy	+26,698	New	+$1.08M	0.03%	684
2013 Q4	–	Sell	-60,765	Closed	-$1.64M	–	930
2013 Q3	$1.64M	Buy	+60,765	New	+$1.71M	0.04%	578

Other funds holding LGND

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PDT Partners's LGND Position: Q4 2016 in Review

PDT Partners sold out of Ligand Pharmaceuticals (LGND) in Q4 2016, closing a stake of 11,061 shares — an estimated $704K sold.

PDT Partners first reported a position in LGND in Q3 2013 and held it in 10 quarters. The position peaked at $7.49M in Q2 2016. 269 funds tracked by Wall St. Rank hold LGND as of Q4 2016.

PDT Partners reported no remaining Ligand Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
PDT Partners sold 11,061 Ligand Pharmaceuticals shares in Q4 2016, an estimated $704K.
PDT Partners first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 10 quarters.
PDT Partners's Ligand Pharmaceuticals position peaked at $7.49M in Q2 2016.
269 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2016.

Based on PDT Partners's 13F filing for Q4 2016, filed 14 Feb 2017.